两种剂型美托洛尔治疗慢性阻塞性肺疾病合并慢性心力衰竭的临床分析

Clinical Analysis of Two Dosage Forms of Metoprolol in the Treatment of Chronic Obstructive Pulmonary Disease with Chronic Heart Failure

目的探究琥珀酸美托洛尔缓释片与酒石酸美托洛尔片治疗慢性阻塞性肺疾病合并慢性心力衰竭的临床效果。方法方便选取该院120例慢性阻塞性肺疾病合并慢性心力衰竭患者为研究对象,选取的时间范围为2016年2月-2019年2月,分为对照组和实验组,每组60例患者,对照组患者进行酒石酸美托洛尔片治疗,实验组采用琥珀酸美托洛尔缓释片治疗。观察两组患者的心功能改善状况、肺功能指标和左心室射血分数。结果研究结果显示,实验组患者的心功能改善状况(95.00%)明显好于对照组(76.67%)(χ~2=13.817,P=0.000);治疗后,实验组的左心室射血分数(40.11±3.56)分,明显高于对照组(35.07±3.24)分(t=8.110。P=0.000);治疗后两组患的平均1 s用力呼气容积(FEV1)、1 s用力呼气容积占预测值百分比(FEV1%)、平均1 s用力呼气容积/用力肺活量(FEV1/FVC)都有所上升,实验组的FEV1、FEV1%和FEV1/FVC分别为(1.51±0.49)L、(56.43±4.79)%和(68.65±6.11)%,明显高于对照组(1.33±0.42)L、(51.22±3.31)%和(61.47±5.73)%(t=2.160,P=0.033;t=6.931,P=0.000;t=6.639,P=0.000),差异有统计学意义(P<0.05)。结论相比于酒石酸美托洛尔片,琥珀酸美托洛尔缓释片对慢性阻塞性肺疾病合并慢性心力衰竭患者的心功能改善效果更好,增加左心室射血分数。

Objective To explore the clinical effect of metoprolol succinate sustained-release tablets and metoprolol tartrate in the treatment of chronic obstructive pulmonary disease with chronic heart failure. Methods One hundred and twenty patients with chronic obstructive pulmonary disease and chronic heart failure in the hospital were convenienty selected as subjects. The time range was from February 2016 to February 2019. All the subjects were divided into control group and experimental group, 60 patients in each group. The control group was treated with metoprolol tartrate tablets, and the experimental group was treated with metoprolol succinate sustained-release tablets, observing the improvement of cardiac function, the changes of lung function indexes before and after treatment and the left ventricular ejection fraction. Results The results of the study showed that the improvement of cardiac function in the experimental group(95.00%) was significantly better than that in the control group(76.67%)(χ~2=13.817;P=0.000);After treatment, the left ventricular ejection fraction of the experimental group(40.11±3.56)points was significantly higher than that of the control group(35.07±3.24)points(t=8.110, P=0.000);after treatment, the average 1 s forced expiratory volume(FEV1), 1 s forced expiratory volume as a percentage of predicted value(FEV1%), and average 1 s forced expiratory volume/forced vital capacity(FEV1/FVC)increased. The FEV1, FEV1% and FEV1/FVC of the experimental group were(1.51±0.49)L,(56.43±4.79)% and(68.65±6.11)% respectively, which were significantly higher than the control group(1.33±0.42)L,(51.22±3.31)% and(61.47±5.73)%(t =2.160, P =0.033;t =6.931, P =0.000;t =6.639, P =0.000), and the difference was statistically significant(P <0.05).Conclusion Compared with metoprolol tartrate tablets, metoprolol succinate sustained-release tablets have better cardiac function improvement in patients with chronic obstructive pulmonary disease and chronic heart failure, which can increase left ventricular ejection fraction.